1. The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
- Author
-
Yuchen Guo, Chu Lin, Xiaoling Cai, Han Wu, Jingya Yan, Zonglin Li, Ruoyang Jiao, Shuzhen Bai, Wenjia Yang, Fang Lv, Geling Liu, Xiaolin Yang, and Linong Ji
- Subjects
Cardiovascular medicine ,Public health ,Science - Abstract
Summary: The association between anti-obesity medications (AOMs) as well as their weight-loss effects and cardiovascular outcomes need to be comprehensively investigated. We searched PubMed, Embase, the Cochrane Center Register of Controlled Trials for Studies, and Clinicaltrial.gov website from the inception to April 2024 and included 129 randomized controlled trials (RCTs) of AOMs. When compared with placebo, every 5 kg weight reduction mediated by AOMs was associated with the reduced risks of 3-point major adverse cardiovascular events (relative risk [RR] 0.72, 95% confidence interval [CI] 0.60–0.85), myocardial infarction (RR 0.75, 95% CI 0.60–0.95), stroke (RR 0.60, 95% CI 0.42–0.85), and heart failure (RR 0.71, 95% CI 0.54–0.95). As for glucagon-like peptide 1 receptor agonist (GLP-1RA)-users, similar cardiovascular benefits were also observed with 5 kg weight loss. This study indicated that the weight reductions mediated by AOMs were associated with cardiovascular benefits observed in AOM-users.
- Published
- 2024
- Full Text
- View/download PDF